<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prognosis and monitoring of idiopathic pulmonary fibrosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prognosis and monitoring of idiopathic pulmonary fibrosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prognosis and monitoring of idiopathic pulmonary fibrosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher Ryerson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brett Ley, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H152955089">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), previously known as cryptogenic fibrosing alveolitis (CFA) in Europe, is the most common type of idiopathic interstitial pneumonia (IIP) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         An American Thoracic Society (ATS)/European Respiratory Society (ERS) consensus statement defines IPF as a spontaneously occurring (idiopathic) specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with a pattern of UIP on high-resolution computed tomography (HRCT) or surgical (thoracoscopic or open) lung biopsy [
         <a href="#rid2">
          2
         </a>
         ]. The importance of careful monitoring and accurate prognostication has increased with the availability of new medications to treat IPF and expanding eligibility for lung transplantation.
        </p>
        <p>
         The prognosis and monitoring of IPF will be reviewed here. The clinical manifestations, diagnosis, and treatment of IPF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H61154306">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of IPF is most often described as one of insidious decline in lung function resulting in progression to respiratory failure and death on average within approximately four to five years after the initial diagnosis [
         <a href="#rid2">
          2
         </a>
         ]. However, there is great variability in disease course among individual patients with IPF, and survival is influenced by several factors including variable progression rates, occurrence of acute exacerbations, and comorbid disease  (
         <a class="graphic graphic_figure graphicRef114394" href="/z/d/graphic/114394.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]
         <strong>
          .
         </strong>
        </p>
        <p class="headingAnchor" id="H2910560838">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         The median survival of IPF has been reported to range from two to five years [
         <a href="#rid4">
          4,5
         </a>
         ]. This estimate reflects the range of average life expectancies observed in cohorts of IPF patients, rather than the limits of an individual patient's life expectancy. This nuance is important, as the actual range of survival of individual IPF patients is quite broad, with up to 20 to 25 percent of patients living beyond 10 years [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         There are several caveats to interpretation of reported survival estimates for IPF.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First, available estimates have largely been generated from cohorts of patients seen at specialty referral centers, and thus may not account for the significant time lags between development of first symptoms, initial detection of pulmonary fibrosis, and referral to an interstitial lung disease (ILD) center [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second, up to 20 percent of patients with IPF will die from causes not directly attributable to their disease (eg, lung cancer, cardiovascular disease) [
         <a href="#rid3">
          3,7
         </a>
         ]. Patients with these and other significant comorbidities are often excluded from clinical trials, resulting in lower than expected short-term (eg, one year) mortality rates compared with general clinical cohorts [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third, it remains unknown how the introduction of approved IPF medications (ie,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         ) and the decreased use of harmful immunosuppressive agents (ie, combination of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ) will influence long-term survival in patients with IPF [
         <a href="#rid9">
          9-12
         </a>
         ]. More recent cohorts suggest longer survival of IPF, which is likely at least partially related to these changes in management [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3527193366">
         <span class="h2">
          Predictors of mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         In light of the variable clinical course, several studies have sought to identify predictors of survival in IPF. Predictors of reduced survival at baseline include older age, male sex, lower forced vital capacity (FVC) percent predicted, lower diffusing capacity of carbon monoxide (DLCO) percent predicted, resting or exertional hypoxemia, greater severity of dyspnea, reduced BMI, lower distance walked on six-minute walk test (6MWT), and greater extent of fibrosis on high-resolution computed tomography (HRCT), among others  (
         <a class="graphic graphic_table graphicRef114395" href="/z/d/graphic/114395.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5,8,14-20
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gender-Age-Physiology (GAP) model
         </strong>
         – The most widely used clinical prediction model is the GAP model, which incorporates age, gender, FVC, and DLCO into a simple point-score index and staging system predictive of one-, two-, and three-year mortality  (
         <a class="graphic graphic_table graphicRef114397" href="/z/d/graphic/114397.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. Likely due to changes in IPF diagnosis and treatment since its initial validation, the GAP model tends to overestimate mortality, particularly in patients with mild disease [
         <a href="#rid8">
          8,20
         </a>
         ]. Several extensions of the GAP model have been derived and validated. These include validation of a modified index that also includes baseline six-minute walk distance and exertional hypoxemia, showing improved discrimination in more recent cohorts [
         <a href="#rid20">
          20
         </a>
         ]. We use the GAP index and staging system, combined with clinical impression that considers multiple additional variables (eg, unintended weight loss, severity of dyspnea, extent of fibrosis on imaging, change in walk distance, exertional hypoxemia) to guide initial patient discussions regarding prognosis, therapeutic options, urgency of lung transplantation, and timeline of palliative approaches.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Longitudinal clinical course
         </strong>
         – Longitudinal clinical course powerfully predicts subsequent survival. In particular, a 10 percent or greater decline in FVC over 6 to 12 months, occurrence of an acute exacerbation, or worsening respiratory symptoms requiring hospitalization all herald high risk for short-term mortality [
         <a href="#rid14">
          14,21,22
         </a>
         ]. IPF is often considered to be an inexorably progressive disease; however, a substantial percentage of patients have a slow progression that suggests improved survival. This has been most clearly demonstrated in the application of recently proposed criteria for progressive pulmonary fibrosis (PPF) to IPF populations [
         <a href="#rid23">
          23
         </a>
         ], with only half of patients meeting criteria for PPF in the first two years of follow-up [
         <a href="#rid24">
          24
         </a>
         ]. Although the concept of PPF is intended for use in non-IPF ILDs primarily to inform management decisions in this population, there is likely applicability to IPF in terms of the prognostic significance of meeting PPF criteria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We follow the trajectory of lung function decline in IPF patients, specifically in FVC and DLCO, every three to six months in order to update prognostic discussions with patients, determine urgency of lung transplantation for potential candidates, and inform treatment decisions (for example, whether to continue antifibrotic therapy, switch antifibrotic therapy, or change focus to palliative and/or hospice care for those who are not candidates for lung transplantation). Longitudinal lung function trajectory is further contextualized with symptomatic and radiologic findings, particularly when marginal physiologic worsening is present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular biomarkers
         </strong>
         – Beyond clinically available information, there is great interest in identifying noninvasive molecular biomarkers to refine prognostication in IPF. Some of the most exciting candidates include several blood proteins that reflect alveolar epithelial cell injury or activation of fibrotic pathways [
         <a href="#rid25">
          25
         </a>
         ], peripheral blood gene expression profiles [
         <a href="#rid26">
          26
         </a>
         ], peripheral blood leukocyte telomere length [
         <a href="#rid27">
          27
         </a>
         ], peripheral blood monocyte count [
         <a href="#rid28">
          28
         </a>
         ], and the mucin 5B (MUC5B) promoter polymorphism  (
         <a class="graphic graphic_table graphicRef114395" href="/z/d/graphic/114395.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2996818422">
         <span class="h2">
          Acute exacerbations
         </span>
         <span class="headingEndMark">
          —
         </span>
         An acute exacerbation of IPF is defined as an acute respiratory deterioration in a patient with IPF along with evidence of new widespread alveolar abnormalities (ie, new bilateral ground glass opacities and/or consolidation on chest HRCT) not otherwise explained by another cause such as heart failure [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         Acute exacerbations occur in approximately 5 to 10 percent of IPF patients per year and carry a very poor prognosis with median survival after an exacerbation of only three to four months and high in-hospital mortality for those presenting with respiratory failure (50 percent overall and 90 percent for those requiring invasive mechanical ventilation) [
         <a href="#rid30">
          30,31
         </a>
         ]. More broadly, several studies have confirmed that hospitalizations for worsening respiratory symptoms, regardless of whether they meet criteria for acute exacerbations, confer a high risk for subsequent mortality [
         <a href="#rid21">
          21,22
         </a>
         ]. The occurrence of acute exacerbation or respiratory hospitalization should therefore prompt reanalysis of expected prognosis and, potentially, goals of care. (See
         <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">
          "Palliative care for adults with nonmalignant chronic lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95552.html" rel="external">
          "Discussing goals of care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1002787214">
         <span class="h2">
          Predicting disease progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several ways that disease progression can be measured in patients with IPF; however, there is no single standard method or set of clinical criteria, and predictors of survival tend to be poor predictors of disease progression [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical parameters
         </strong>
         – Clinical information that is predictive of survival does not appear to meaningfully predict rate of progression [
         <a href="#rid32">
          32
         </a>
         ]. One notable exception is that patients with a family history of pulmonary fibrosis due to mutations in telomere-maintenance genes may have a faster average rate of progression than those with sporadic IPF [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FVC
         </strong>
         – Decline in FVC, as an indirect measure of worsening fibrosis that results in increased lung stiffness, has become the most commonly accepted measure of disease progression in IPF. Data from the placebo groups of multiple IPF trials indicate that the average annual rate of FVC decline is approximately 200 mL, which is approximately halved by both
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         [
         <a href="#rid3">
          3,9,34
         </a>
         ]. Rate of decline in FVC among individuals again is highly variable, with approximately one-third each in placebo arms experiencing stability, marginal decline (ie, 5 to 10 percent), or significant decline (ie, &gt;10 percent) in FVC over one year [
         <a href="#rid22">
          22
         </a>
         ]. Interestingly, decline in FVC at the individual patient level may be more stepwise than linear over time, and past trajectory of FVC does not predict future trajectory of FVC in the short term [
         <a href="#rid32">
          32,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reduction in FVC decline was the primary efficacy end point in the landmark trials that led to US Food and Drug Administration (FDA) approval of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         for IPF [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DLCO
         </strong>
         – DLCO is limited as a practical measure of progression over time due to its lower interest reproducibility and relative nonspecificity for ILD, but large declines (ie, 15 percent or greater) have been considered an indication of significant progression [
         <a href="#rid3">
          3
         </a>
         ]. Smaller declines in DLCO (ie, 5 to 15 percent) may be clinically meaningful when contextualized with other measures of disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HRCT
         </strong>
         – Quantification of lung fibrosis on HRCT over time is an attractive and potentially more direct measure of disease progression than FVC but is not currently applicable to clinical practice due to lack of rapid and reproducible quantification methods. Automated software algorithms for quantification of HRCT fibrosis may change this in the future [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Imaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular biomarkers
         </strong>
         – There is great interest in identifying molecular biomarkers that can predict rate of disease progression and help identify patients who are more or less likely to benefit from IPF medications or who need urgent evaluation for lung transplantation  (
         <a class="graphic graphic_table graphicRef114395" href="/z/d/graphic/114395.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid25">
          25,37-39
         </a>
         ]. While several molecular biomarkers predict survival and/or disease progression, none has been demonstrated to predict response to antifibrotic therapy, thus limiting their clinical value [
         <a href="#rid40">
          40,41
         </a>
         ]. One exception is that shorter peripheral blood telomere length appears to predict harm from immunosuppressive therapies, but immunosuppression is no longer recommended for patients with IPF [
         <a href="#rid42">
          42
         </a>
         ]. Molecular biomarkers are not widely available nor commonly measured in clinical practice for the management of IPF.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H55137302">
         <span class="h1">
          MONITORING
         </span>
        </p>
        <p class="headingAnchor" id="H3966446408">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major reasons to monitor patients with IPF are to assess potential disease progression that might prompt a change in therapy and to identify comorbidities and complications that will influence when to initiate or stop antifibrotic therapy, when to initiate or titrate oxygen therapy, when to refer and list for lung transplantation, and when to initiate palliative measures. The management of IPF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         As there are limited data and no clear consensus on how to monitor patients with IPF, most recommendations are based on extrapolated evidence and expert opinion. The specific monitoring strategy is driven by clinical need that is assessed on a case-by-case basis. The type and frequency of monitoring evolves over the course of the disease, with symptom assessment and pulmonary function measurements being the cornerstones of disease monitoring.
        </p>
        <p>
         Early in disease, patients are typically monitored at three- to six-month intervals, with more frequent monitoring considered in patients with more advanced or rapidly progressive disease. Specific monitoring is also required by some funding agencies in order to acquire or maintain financial coverage for antifibrotic medication.
        </p>
        <p>
         Patients with worsening symptoms, pulmonary function, or chest imaging should have these findings contextualized with results from other domains to determine whether IPF progression is the cause of this worsening. Progression of IPF may prompt additional confirmatory tests, initiation or change in IPF pharmacotherapy, consideration of lung transplantation, or initiation of palliative therapies.
        </p>
        <p class="headingAnchor" id="H3081323161">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common symptoms of IPF are dyspnea, reduced exertional capacity, and cough that is nonproductive or minimally productive. These symptoms are present in the majority of patients at the time of diagnosis and increase in prevalence and severity during the course of disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyspnea
         </strong>
         – Worsening dyspnea is a primary indicator of disease progression [
         <a href="#rid43">
          43-45
         </a>
         ], including acute exacerbations of IPF [
         <a href="#rid30">
          30
         </a>
         ], and should be assessed at every patient encounter. The optimal method of assessment has not been determined, but in clinical practice dyspnea is typically assessed by a qualitative history or simple measurements such as the modified Medical Research Council (mMRC) breathlessness scale (
         <a class="calc calc_professional" href="/z/d/html/142813.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef86426" href="/z/d/graphic/86426.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid46">
          46
         </a>
         ]; however, this scale is relatively limited and may lack sensitivity to anything less than major progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Structured dyspnea questionnaires that provide a summary score (eg, University of San Diego Shortness of Breath Questionnaire) have been frequently used in IPF clinical trials; however, the clinical utility of these more detailed and time-consuming assessments is unclear, and most questionnaires lack complete validation in IPF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dyspnea is also a common manifestation of multiple comorbidities in IPF (eg, chronic obstructive pulmonary disease, pulmonary hypertension, cardiovascular disease), and it is necessary to consider worsening dyspnea in the context of other measures of disease progression. This allows determination of whether worsening dyspnea is due to IPF progression, thus informing management decisions related to IPF pharmacotherapy, lung transplantation, and palliative therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exercise capacity
         </strong>
         – Exercise capacity worsens as IPF progresses and is a major source of morbidity and loss of independence. There is no established strategy for measurement of physical function in IPF, with possibilities including patient history, standardized questionnaires, and direct measurements of exercise performance or physical activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients should be questioned about their exercise capacity at each clinical encounter. These questions focus on what distance patients can walk and whether they can climb stairs, with or without oxygen, as well as other questions related to how well the patient is managing in his or her home environment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cough
         </strong>
         – Cough adversely affects quality of life in patients with IPF and tends to worsen as the disease progresses [
         <a href="#rid47">
          47,48
         </a>
         ]. The best method of assessment for individual patients has not been determined; in our practice we use a qualitative assessment of frequency and severity. Research studies have assessed cough by using a visual analog scale (eg, marking an "x" on a 10 cm straight line), cough counters, structured questionnaires (eg, Leicester Cough Questionnaire), and as a dichotomous variable based on patient report [
         <a href="#rid49">
          49,50
         </a>
         ]. These methods are not commonly used in a clinical setting, as they are often time consuming and lack complete validation in IPF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other symptoms
         </strong>
         – At each encounter we explore the following additional symptoms:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other consequences of IPF (eg, impaired sleep, depression, anxiety, pulmonary hypertension) (see
         <a class="local">
          'Complications and comorbidities'
         </a>
         below)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Common comorbidities (eg, COPD, lung cancer, cardiovascular disease) (see
         <a class="local">
          'Complications and comorbidities'
         </a>
         below)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Features that may identify a diagnosis other than IPF (eg, rheumatic disease, hypersensitivity pneumonitis, pneumoconiosis)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Potential adverse effects of IPF pharmacotherapies (see
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Dose and administration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Dose and administration'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1642078877">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs) are a key component of disease monitoring in IPF. The most common PFT variables that are regularly monitored in IPF are forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO) [
         <a href="#rid51">
          51-53
         </a>
         ]; lung plethysmography provides additional useful data in some patients [
         <a href="#rid54">
          54
         </a>
         ]. FVC and DLCO are consistently strong predictors of mortality in IPF and are key variables in determining the timing for lung transplantation [
         <a href="#rid5">
          5,14,15
         </a>
         ]. (See
         <a class="local">
          'Predictors of mortality'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Lung transplantation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests to order
         </strong>
         – PFTs (ie, spirometry, DLCO, six-minute walk test [6MWT]) are usually performed at intervals of three to six months in patients with IPF, with more or less frequent testing depending on the degree of symptoms and rate of worsening. For patients with combined pulmonary fibrosis and emphysema (CPFE) or discordant changes in FVC and DLCO, lung volumes by plethysmography may help clarify the physiology. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation
         </strong>
         – An absolute decline in FVC or DLCO of at least 10 percent over 6 to 12 months predicts an increased risk of mortality [
         <a href="#rid8">
          8,14,21,22,35,44,55-58
         </a>
         ], and some studies have suggested smaller absolute declines in FVC of 5 percent also portend a worse prognosis [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with a decline in FVC and/or DLCO should have this worsening interpreted in the context of other key features of disease progression, such as symptoms and high-resolution computed tomography (HRCT), given the inherent variability of PFTs and lack of specificity. Correlation of PFT changes with imaging findings should be considered in patients with marginal decline in PFT (eg, decline in FVC of 5 to 10 percent) and/or marginally worse symptoms. Similarly, repeat PFTs may be appropriate in patients with discordant findings in which disease progression is suggested by one modality but not another.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with CPFE have relative preservation of spirometric values and slower decline in FVC compared with patients with isolated IPF [
         <a href="#rid57">
          57,61
         </a>
         ], indicating the need to consider other measures of disease progression in these patients. (See
         <a class="local">
          'Combined pulmonary fibrosis and emphysema'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Six-minute walk test
         </strong>
         – The 6MWT is the most common method of measuring exercise capacity in patients with IPF (see
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults", section on 'Six-minute walk test'
         </a>
         ). The 6MWT is a well-described standardized test that has been extensively studied in chronic lung diseases, including IPF [
         <a href="#rid62">
          62,63
         </a>
         ]. The key variables obtained from the 6MWT are the distance walked and extent of hypoxemia measured by pulse oximetry. A change in six-minute walk distance (6MWD) of approximately 30 meters is considered a clinically important change in IPF [
         <a href="#rid64">
          64-66
         </a>
         ]; however, it is unknown what amount of change in oxygenation is clinically significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both baseline and change in 6MWD over six months are strong and independent predictors of mortality [
         <a href="#rid18">
          18,64,67
         </a>
         ]. Lower values for the oxygen saturation nadir also indicate a worse prognosis [
         <a href="#rid43">
          43,68
         </a>
         ]. These findings suggest there may be a prognostic role for repeating the 6MWT every six months, and particularly in patients with more severe disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The 6MWT furthermore provides data on when to initiate ambulatory oxygen supplementation. Based on anecdotal experience, patients with IPF who have exertional desaturation derive symptomatic benefit from supplemental oxygen during exertion, although the long-term benefit of supplemental oxygen is not established in patients with isolated exertional hypoxemia and preserved oxygen saturation at rest [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Home spirometry
         </strong>
         – More frequent monitoring of pulmonary function with daily home spirometry is being explored as a way to identify acute exacerbations more quickly. One study suggested that daily home spirometry is feasible and may allow earlier identification of worsening disease [
         <a href="#rid70">
          70
         </a>
         ]. Another study monitored 25 patients with daily home spirometry and questionnaires. Adherence to monitoring for 24 weeks was over 90 percent, although it declined over time [
         <a href="#rid71">
          71
         </a>
         ]. Baseline in-laboratory spirometry correlated well with home spirometry results. While home spirometry may be helpful as an outcome measure for clinical trials, it requires further validation prior to routine clinical use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Portable activity monitors
         </strong>
         – There are multiple portable activity monitors that provide a variety of data related to physical function that may be relevant to patients [
         <a href="#rid72">
          72
         </a>
         ]. These can help motivated patients track their own activity level on a day-to-day basis; however, there are currently insufficient data to justify a recommendation for their clinical use.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H546340226">
         <span class="h2">
          Oxygenation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with advanced IPF frequently have resting hypoxemia that meets the threshold for oxygen supplementation (ie, pulse oxygen saturation [SpO
         <sub>
          2
         </sub>
         ] ≤88 percent), which can be provided continuously, with ambulation, and nocturnally as necessary. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         Development of worsening hypoxemia and increasing oxygen requirements are common indicators of disease progression and increased risk of mortality [
         <a href="#rid43">
          43-45,68,73,74
         </a>
         ]; however, there is no established method for identifying which patients require assessment for resting, exertional, or nocturnal hypoxemia. Severe dyspnea with ambulation, functional limitation secondary to dyspnea, moderately or severely reduced DLCO, and the presence of pulmonary hypertension are common features that indicate the need to consider ambulatory oxygen supplementation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulse oximetry
         </strong>
         – Assessment of resting oxygenation by pulse oximetry is easily performed and often obtained at each clinical encounter, particularly in patients with advanced disease. Walking oximetry, often obtained as a component of a 6MWT [
         <a href="#rid62">
          62,63
         </a>
         ], requires a modest amount of additional time and health care resources and should be performed in patients with clinical suspicion of exertional hypoxemia. (See
         <a class="local">
          'Pulmonary function tests'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults", section on 'Six-minute walk test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Portable oximeters
         </strong>
         – Some patients use portable pulse oximeters to monitor disease progression and titrate home oxygen use. These devices can provide useful data on the extent of hypoxemia with a patient's usual amount of physical activity, but may be less reliable than regularly calibrated in-hospital devices. Low readings can be helpful to indicate the need for a formal oxygen needs assessment through a pulmonary function laboratory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overnight oximetry
         </strong>
         – Overnight oximetry is obtained in patients with clinical suspicion of nocturnal hypoxemia and/or sleep-disordered breathing (eg, due to poor sleep quality, morning headaches, daytime sleepiness, snoring). Given the absence of clear guidance on how frequently patients should be assessed, most patients are tested at baseline and when there is evidence of worsening disease with concern of nocturnal hypoxemia. As described below, the high prevalence of obstructive sleep apnea in patients with IPF indicates the need to consider overnight oximetry and polysomnography in all IPF patients even when there is a low suspicion for nocturnal hypoxemia. (See
         <a class="local">
          'Complications and comorbidities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arterial blood gas
         </strong>
         – An arterial blood gas is obtained in some patients as a complementary study to pulse oximetry in patients with borderline findings; however, this is a more invasive test and is often not necessary to demonstrate the presence of clinically significant hypoxemia. Respiratory acidosis is a rare finding in IPF and an arterial blood gas is infrequently obtained for acid-base assessment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H789244529">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         HRCT is an essential component of the diagnostic process for all interstitial lung diseases (ILDs), but the role of HRCT for monitoring IPF progression is less clear. In clinical practice, HRCTs are primarily assessed qualitatively to confirm or exclude significant disease progression, particularly in patients with discordant symptoms and physiology. Many clinicians, including ourselves, repeat the HRCT every one to two years in patients with IPF, with the primary goals of identifying any change in morphology, clarifying disease progression, or detecting a new comorbidity (eg, lung malignancy).
        </p>
        <p>
         By contrast, conventional chest radiography has a limited role for routine monitoring of disease progression in patients with IPF but can be useful as an initial screen for potential etiologies of acute respiratory worsening and can occasionally suggest other comorbidities.
        </p>
        <p>
         HRCT with or without a rule-out pulmonary embolism protocol is an important test in the evaluation of an acute respiratory worsening (eg, acute exacerbation of IPF). Given the baseline abnormalities in IPF, comparison of HRCT findings during an episode of acute worsening of dyspnea with a previous examination is essential. (See
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         Formal scoring of fibrosis severity on HRCT is primarily used in research and specialized settings. HRCTs can be scored visually by an experienced CT radiologist to provide a total fibrosis score (ie, percent of affected lung), or quantitatively calculated using a computer-based algorithm to again produce a fibrosis score. Previous studies have shown that both visual and computer-based scoring of fibrosis severity provide prognostic information beyond standard clinical and physiologic variables [
         <a href="#rid36">
          36,75-82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1288856573">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         No laboratory studies have been established as having a prognostic role in IPF. Laboratory testing is focused on characterization of intercurrent illnesses, acute exacerbations, and adverse effects of medication. The evaluation of acute exacerbations of IPF is described separately. (See
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis", section on 'Laboratory testing'
         </a>
         .)
        </p>
        <p>
         Serologic evaluation for a connective tissue disease is recommended in the initial evaluation of IPF [
         <a href="#rid2">
          2
         </a>
         ], including antinuclear antibody, rheumatoid factor, and anti-cyclic citrullinated peptide. Follow-up serologic testing may be appropriate in some patients, although consensus is lacking. Up to 10 percent of patients with a previous diagnosis of IPF can later develop a connective tissue disease [
         <a href="#rid83">
          83,84
         </a>
         ], indicating that repeat serologic testing should be performed intermittently in IPF patients with features suggestive of a potential rheumatic disease. Conversely, up to 30 percent of IPF patients have positive autoimmune serology despite no other evidence of a rheumatic disease [
         <a href="#rid83">
          83,85-88
         </a>
         ], indicating the poor specificity of autoimmune serologies for overt connective tissue disease in this population.
        </p>
        <p>
         Previous studies have suggested a potential prognostic role for molecular markers of lung damage  (
         <a class="graphic graphic_table graphicRef114395" href="/z/d/graphic/114395.html" rel="external">
          table 1
         </a>
         ); however, these markers lack sufficient validation to support their clinical use for monitoring of IPF progression.
        </p>
        <p>
         The laboratory tests used to monitor for adverse effects of IPF pharmacotherapies are described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Dose and administration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Dose and administration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1223865962">
         <span class="h1">
          COMPLICATIONS AND COMORBIDITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         IPF is associated with several complications and comorbidities that are related to the underlying physiologic consequences of IPF or to common IPF risk factors that include older age and a history of cigarette smoking. These complications and comorbidities include chronic obstructive pulmonary disease (COPD), cardiovascular disease, pulmonary hypertension, lung cancer, and obstructive sleep apnea as described below. These add to the symptomatic, functional, and physiologic consequences of IPF and are frequently associated with high mortality; however, there are no standardized recommendations for how patients with IPF should be screened for these disorders.
        </p>
        <p>
         In addition, IPF patients have a high frequency of gastroesophageal reflux, depression, and anxiety that often reach clinically relevant thresholds of severity, indicating the need for regular assessment of these conditions [
         <a href="#rid89">
          89,90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H643858394">
         <span class="h2">
          Combined pulmonary fibrosis and emphysema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Significant comorbid emphysema is often identified on chest imaging in patients with IPF [
         <a href="#rid89">
          89
         </a>
         ], although patients with combined pulmonary fibrosis and emphysema (CPFE) frequently do not meet physiologic criteria for COPD. (See
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Disease monitoring is not different in patients with CPFE compared with patients with isolated IPF, with the exception that patients with concurrent emphysema appear to have relatively preserved spirometric values and less rapid decline in forced vital capacity (FVC), thus indicating the need to consider other measures of disease progression in these patients (eg, diffusing capacity of carbon monoxide [DLCO], oxygenation, imaging) [
         <a href="#rid57">
          57,61,91
         </a>
         ]. The management of COPD is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         .)
        </p>
        <p>
         Patients with CPFE have a high incidence of pulmonary hypertension and lung cancer [
         <a href="#rid92">
          92-97
         </a>
         ], suggesting the potential need for a more routine and thorough assessment for these complications in this population.
        </p>
        <p class="headingAnchor" id="H2728713666">
         <span class="h2">
          Cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular comorbidities, such as dysrhythmias (5 to 20 percent), heart failure (4 to 26 percent), and coronary artery disease (CAD; 3 to 68 percent), are common in the age group of patients with IPF [
         <a href="#rid89">
          89
         </a>
         ]. Among a group of 73 patients with IPF undergoing evaluation for potential lung transplantation, 29 percent had significant CAD, and mortality in these patients was higher than in those without significant CAD [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         As dyspnea can be caused by any of these cardiovascular comorbidities, evaluation with electrocardiogram, stress radionuclide myocardial perfusion imaging, or stress echocardiography may be prudent when worsening dyspnea is not fully explained by the severity of IPF. (See
         <a class="medical medical_review" href="/z/d/html/1502.html" rel="external">
          "Selecting the optimal cardiac stress test", section on 'Patient cannot exercise to a satisfactory workload'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2173675445">
         <span class="h2">
          Pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension is common in patients with advanced IPF (30 to 50 percent) and particularly in patients with CPFE, but with substantial variability in prevalence that is related to differences in study populations [
         <a href="#rid89">
          89
         </a>
         ]. There are no consensus recommendations for when patients with IPF should be screened for pulmonary hypertension by echocardiography.
        </p>
        <p>
         For patients with chronic lung disease in general, the following findings may suggest the development of pulmonary hypertension and warrant further assessment of pulmonary artery systolic pressure with transthoracic echocardiography:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exertional dyspnea or hypoxemia that is not fully explained by the degree of parenchymal lung disease or severity of the underlying sleep disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disproportionately low DLCO compared with degree of spirometric or lung volume reduction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid decline of pulse oxygen saturation with exertion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exertional chest pain (eg, atypical or nonanginal chest pain), syncope or near-syncope, increased intensity of or a palpable pulmonic component of the second heart sound, a narrowly split-second heart sound, elevated jugular venous pressure, peripheral edema, right-axis deviation on electrocardiogram, right atrial enlargement, and/or right ventricular hypertrophy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enlarged pulmonary arteries (eg, main pulmonary artery &gt;29 mm) on high-resolution computed tomography (HRCT).
        </p>
        <p>
        </p>
        <p>
         The evaluation and treatment of pulmonary hypertension in patients with chronic lung disease is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1379584651">
         <span class="h2">
          Lung malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IPF have an approximately fivefold higher risk of lung malignancy compared with a matched control population [
         <a href="#rid89">
          89,99,100
         </a>
         ], and this increased risk exists independent of smoking history [
         <a href="#rid100">
          100
         </a>
         ]. Mortality is also significantly higher when IPF is complicated by lung cancer compared with IPF without lung cancer [
         <a href="#rid89">
          89,95,101
         </a>
         ]. Despite the relatively high incidence and poor outcome, the role of lung cancer screening in IPF is unclear, as many IPF patients would not tolerate surgical resection or other primary treatment modalities of chemotherapy and radiotherapy.
        </p>
        <p>
         Intermittent screening for lung malignancy with low-dose computed tomography (CT) is reasonable for patients with IPF who meet guideline criteria for lung cancer screening  (
         <a class="graphic graphic_table graphicRef64078" href="/z/d/graphic/64078.html" rel="external">
          table 4
         </a>
         ) and would tolerate potential therapy. Screening for lung malignancy is also appropriate in patients undergoing transplant evaluation and in other patients for whom identification of a lung malignancy would alter other therapeutic or prognostic decisions.
        </p>
        <p>
         The frequency of monitoring in these situations is not standardized, and it is unknown whether the annual low-dose CT protocol from the National Lung Screening Trial is appropriate in patients with IPF in whom screening is being considered [
         <a href="#rid102">
          102
         </a>
         ]. The screening and evaluation of lung cancer is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">
          "Screening for lung cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130496.html" rel="external">
          "Evaluation and management of lung cancer in patients with interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1388840836">
         <span class="h2">
          Obstructive sleep apnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several small cohort studies have suggested that moderate-to-severe obstructive sleep apnea is present in approximately half of patients with IPF [
         <a href="#rid89">
          89
         </a>
         ], with some studies showing increased morbidity and mortality in patients with sleep desaturation [
         <a href="#rid103">
          103-106
         </a>
         ]. Risk factors for sleep-disordered breathing are similar to those of a general population, with no clear association of IPF severity with obstructive or central events [
         <a href="#rid103">
          103,107
         </a>
         ].
        </p>
        <p>
         Common screening tools for sleep-disordered breathing have not been validated in IPF and may be inadequate to exclude disease in this setting [
         <a href="#rid108">
          108
         </a>
         ], indicating the need for a high clinical suspicion and low threshold for screening with overnight oximetry and potentially polysomnography. The screening and evaluation of sleep-disordered breathing is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1682315545">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1662583373">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Natural history
         </strong>
         – The natural history of idiopathic pulmonary fibrosis (IPF) is most often described as one of insidious decline in lung function with progression to respiratory failure and death over approximately four years. However, there is great variability in individual progression rate, occurrence of acute exacerbation, and comorbid disease. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of disease progression
         </strong>
         – At baseline, we use the Gender-Age-Physiology (GAP) index and staging system, combined with clinical impression, to guide patient discussion regarding prognosis, therapeutic options, urgency of lung transplantation, and timeline of palliative approaches  (
         <a class="graphic graphic_table graphicRef114397" href="/z/d/graphic/114397.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Predictors of mortality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We update the initial risk assessment over time, primarily based on dyspnea, oxygen requirement, pulmonary function tests (PFTs), respiratory hospitalizations, and "acute exacerbations" of idiopathic pulmonary fibrosis (AE-IPF)  (
         <a class="graphic graphic_table graphicRef114395" href="/z/d/graphic/114395.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Predicting disease progression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring strategy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms of IPF, particularly dyspnea, cough, and exertional capacity, should be monitored at every patient encounter, typically occurring every three to six months or more frequently, if clinically indicated. (See
         <a class="local">
          'Symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We monitor pulmonary function every three to six months, or more frequently if symptoms change. The rate of decline in forced vital capacity (FVC) is highly variable; each year, approximately one-third of patients experience stability, one-third marginal decline (ie, 5 to 10 percent), and one-third significant decline (ie, &gt;10 percent). (See
         <a class="local">
          'Pulmonary function tests'
         </a>
         above and
         <a class="local">
          'Predicting disease progression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oxygenation is monitored using in-office pulse oximetry at rest and during six-minute walk testing, with these measurements obtained every three to six months, or more frequently if symptoms change. (See
         <a class="local">
          'Oxygenation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitoring for adverse effects of IPF pharmacotherapies should be performed as per recommendations for each medication. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Dose and administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up imaging
         </strong>
         – Qualitative high-resolution computed tomography (HRCT) severity assessment should be performed at baseline. Repeat imaging is usually performed in response to changes in symptoms, pulmonary function, or oxygenation. In addition, HRCT may be obtained every one to two years to evaluate changes in morphology, investigate potential causes of acute worsening, clarify discordant changes in symptoms and physiology, and identify malignancy. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serologic testing
         </strong>
         – We suggest obtaining autoimmune serologies (ie, antinuclear antibody, rheumatoid factor, and anti-cyclic citrullinated peptide) at baseline. Repeat or additional serologic testing is performed in patients with features suggestive of an underlying rheumatic disease. (See
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of worsening symptoms
         </strong>
         – Patients with worsening symptoms, pulmonary function, or chest imaging should have these findings contextualized with results from other domains to determine whether IPF progression is the cause of this worsening, or whether a comorbidity or complication is responsible. (See
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="local">
          'Complications and comorbidities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Progression of IPF may prompt additional confirmatory tests, initiation or change in IPF pharmacotherapy, consideration of lung transplantation, or initiation of palliative therapies. (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications and comorbidities
         </strong>
         – Assessment for complications and comorbidities of IPF (eg, emphysema, cardiovascular disease, pulmonary hypertension, lung cancer, obstructive sleep apnea) is typically performed at baseline; reassessment during follow-up is guided by the initial results and changes in symptoms, lung function, and imaging. (See
         <a class="local">
          'Complications and comorbidities'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011; 184:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One 2016; 11:e0151425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Bradford WZ, Weycker D, et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016; 113:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryerson CJ, Kolb M. The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy? Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comes A, Wong AW, Fisher JH, et al. Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest 2022; 161:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khor YH, Gutman L, Abu Hussein N, et al. Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study. Chest 2021; 160:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandel A, Pastre J, Valery S, et al. Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax 2023; 78:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durheim MT, Collard HR, Roberts RS, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med 2015; 3:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterniti MO, Bi Y, Rekić D, et al. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc 2017; 14:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hambly N, Farooqi MM, Dvorkin-Gheva A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 2022; 60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014; 307:L681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5:205ra136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreuter M, Lee JS, Tzouvelekis A, et al. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2021; 204:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 2015; 46:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016; 194:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016; 48:1710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014; 145:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salisbury ML, Lynch DA, van Beek EJ, et al. Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. Am J Respir Crit Care Med 2017; 195:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015; 3:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herazo-Maya JD, Sun J, Molyneaux PL, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med 2017; 5:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 2017; 5:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neighbors M, Cabanski CR, Ramalingam TR, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med 2018; 6:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dressen A, Abbas AR, Cabanski C, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med 2018; 6:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton CA, Zhang D, Oldham JM, et al. Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019; 200:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005; 60:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng JZ, Wilcox PG, Glaspole I, et al. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology 2017; 22:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Manen MJ, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev 2016; 25:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017; 49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhakta NR, McGowan A, Ramsey KA, et al. European Respiratory Society/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update. Eur Respir J 2023; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011; 38:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salisbury ML, Xia M, Zhou Y, et al. Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest 2016; 149:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013; 144:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014; 44:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD, du Bois RM, Albera C, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med 2015; 109:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell AM, Adamali H, Molyneaux PL, et al. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016; 194:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johannson KA, Vittinghoff E, Morisset J, et al. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hur SA, Guler SA, Khalil N, et al. Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease. Ann Am Thorac Soc 2019; 16:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hook JL, Arcasoy SM, Zemmel D, et al. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Elicker BM, Hartman TE, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 2014; 273:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008; 177:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maldonado F, Moua T, Rajagopalan S, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014; 43:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oda K, Ishimoto H, Yatera K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res 2014; 15:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob J, Bartholmai BJ, Rajagopalan S, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J 2017; 49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008; 246:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. Am J Respir Crit Care Med 2018; 198:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang BH, Park JK, Roh JH, et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci 2013; 28:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono M, Nakamura Y, Enomoto N, et al. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One 2014; 9:e94775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Kim EJ, Lynch KL, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med 2013; 107:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moua T, Zamora Martinez AC, Baqir M, et al. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014; 15:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moua T, Maldonado F, Decker PA, et al. Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis. Mayo Clin Proc 2014; 89:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; 46:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YJ, Choi SM, Lee YJ, et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PLoS One 2017; 12:e0184300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Hansell DM, Sverzellati N, et al. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017; 196:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology 2014; 19:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwak N, Park CM, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med 2014; 108:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015; 147:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo HJ, Do KH, Lee JB, et al. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis. PLoS One 2016; 11:e0161437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010; 104:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007; 101:2534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SW, Dobelle M, Padilla M, et al. Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis. Ann Am Thorac Soc 2019; 16:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittaker Brown SA, Padilla M, Mhango G, et al. Outcomes of Older Patients with Pulmonary Fibrosis and Non-Small Cell Lung Cancer. Ann Am Thorac Soc 2019; 16:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnan V, McCormack MC, Mathai SC, et al. Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis. Chest 2008; 134:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mermigkis C, Stagaki E, Amfilochiou A, et al. Sleep quality and associated daytime consequences in patients with idiopathic pulmonary fibrosis. Med Princ Pract 2009; 18:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med 2013; 9:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myall KJ, West AG, Martinovic JL, et al. Nocturnal Hypoxemia Associates With Symptom Progression and Mortality in Patients With Progressive Fibrotic Interstitial Lung Disease. Chest 2023; 164:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sommerwerck U, Kleibrink BE, Kruse F, et al. Predictors of obstructive sleep apnea in lung transplant recipients. Sleep Med 2016; 21:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136:772.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113935 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21471066" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20935110" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21729893" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22586007" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A multidimensional index and staging system for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21719755" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27023440" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25614172" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836312" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26915984" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25806913" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22607134" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29348187" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21616999" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12663338" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22241745" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34788669" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311766" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33905679" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35332096" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25890798" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28388260" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35486072" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35273032" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25260757" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Molecular biomarkers in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24089408" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24948432" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33434107" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23695349" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27299520" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26232481" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26938706" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27540018" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836310" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24231810" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Predicting pulmonary fibrosis disease course from past trends in pulmonary function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27767347" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25770676" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28942086" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29150411" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072107" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29891356" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566847" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20413545" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12773325" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11673205" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22336677" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994268" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21615619" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cough predicts prognosis in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28544079" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27581827" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cough in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16204605" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Standardisation of the single-breath determination of carbon monoxide uptake in the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16055882" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Standardisation of spirometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28049168" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37500112" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : European Respiratory Society/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15653980" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12773329" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148225" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26425858" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22426899" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19840957" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23370641" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25359356" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25359355" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131468" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996335" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25956020" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16778159" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917227" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27783918" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27089018" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28679608" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30211616" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19074597" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21885386" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24927326" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Idiopathic pulmonary fibrosis: CT and risk of death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17975197" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15894598" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23563264" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24479411" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27811068" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235106" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29684284" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23678265" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24736601" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21565966" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Autoimmune-featured interstitial lung disease: a distinct entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23186614" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25472884" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582190" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26424523" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28892504" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28657784" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19225068" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25198924" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24462477" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Lung cancer risk among patients with combined pulmonary fibrosis and emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25166895" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The impact of lung cancer on survival of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27618692" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16204587" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20199856" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17870458" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30892054" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30990757" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Outcomes of Older Patients with Pulmonary Fibrosis and Non-Small Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714641" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Reduced lung-cancer mortality with low-dose computed tomographic screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18625669" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19060484" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Sleep quality and associated daytime consequences in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23772193" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37187434" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Nocturnal Hypoxemia Associates With Symptom Progression and Mortality in Patients With Progressive Fibrotic Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27448482" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Predictors of obstructive sleep apnea in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567497" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Obstructive sleep apnea is common in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
